Compare Oklo Inc (OKLO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oklo Inc vs Sanofi SA — how do they compare? Oklo Inc trades at $34.7 (market cap $6.43B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 14.8× Oklo Inc's market cap, and Sanofi SA pays a 6.01% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oklo Inc for 32 Days and Sanofi SA for 94 Days on average.
| OKLO | SNY | |
|---|---|---|
Market Cap | $6.43B | $95.18B |
Volume | 16,238,368 | 2,995,646 |
Sector | Utilities | Health |
52-Week High | $174.14 | $52.34 |
52-Week Low | $34.57 | $39.51 |
Typical Hold Time | 32 Days | 94 Days |
Enterprise Value | $3.97B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKLO trades at $34.57, down 6.11% with bearish technical signals despite strong analyst support. The company shows no revenue in 2025 with significant losses (-$105.66M net income) and negative margins, though cash flow from financing provides runway. Recent news highlights nuclear sector volatility and OKLO's $1 billion stock sale raising dilution concerns.
Outlook hinges on project execution amid high risk-reward dynamics. Analyst consensus is bullish (71% Buy) with a $78.63 price target, but profitability challenges and cash burn pose substantial risks. Success depends on commercializing its nuclear reactor pipeline to capitalize on the growing AI power demand.
Sanofi (SNY) trades at $40.23, showing minimal daily movement with a 0.07% gain. The stock presents mixed signals with bearish technical indicators but strong fundamental performance, including three consecutive quarterly earnings beats. Recent expansion of the immunology alliance with Regeneron through an $8 billion deal highlights strategic growth initiatives. Valuation metrics show a P/E of 22.14 and P/S of 1.77, while profitability remains solid with a 72.77% gross margin.
SNY offers steady growth potential driven by pipeline expansion and Dupixent momentum, though patent expiration risks loom. Analyst sentiment is cautiously optimistic with 44% buy ratings, but technical weakness and projected 2026 earnings decline present near-term headwinds. The stock represents a balanced opportunity for long-term investors seeking pharmaceutical exposure with manageable risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
